Basic information Safety Supplier Related

LDN 193189 hydrochloride

Basic information Safety Supplier Related

LDN 193189 hydrochloride Basic information

Product Name:
LDN 193189 hydrochloride
Synonyms:
  • LDN-193189 2HCl
  • LDN 193189 dihydrochloride
  • 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride
  • Viomycin LDN 193189 Dihydrochloride
  • DM-3189 2HCl
  • LDN-193189 2HC
  • LDN-193189 (DM3189) 2HCl
  • LDN-193189 2HCl|||DM-3189 2HCl
CAS:
1435934-00-1
MF:
C25H24Cl2N6
MW:
479.40426
Mol File:
1435934-00-1.mol
More
Less

LDN 193189 hydrochloride Chemical Properties

storage temp. 
-20°C
solubility 
Soluble in DMSO or in Water (up to 5 mg/ml)
form 
solid
color 
Orange-yellow
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 2 months.
More
Less

LDN 193189 hydrochloride Usage And Synthesis

Description

LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC50 value of 4.9 nM. In in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively). LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.

Uses

LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3].

in vivo

LDN-193189 (i.p.; 3 mg/kg; daily; for 35 days) might affect the interaction between breast cancer cells and the bone environment[3].
LDN-193189 (i.p.; 3 mg/kg; single) shows a reduction in ectopic ossification and functional impairment[1].

storage

-20°C

References

[1] BMP type 1 receptor inhibition reduces heterotropic ossification
[2] STUART M CHAMBERS. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors[J]. Nature biotechnology, 2012, 30 7: 715-720. DOI:10.1038/nbt.2249
[3] FAITH R KREITZER. A robust method to derive functional neural crest cells from human pluripotent stem cells.[J]. American journal of stem cells, 2013, 2 2: 119-131.
[4] YU-CHEN LEE. BMP4 promotes prostate tumor growth in bone through osteogenesis.[J]. Cancer research, 2011: 5194-5203. DOI:10.1158/0008-5472.can-10-4374

LDN 193189 hydrochlorideSupplier

UHN Shanghai Research & Development Co., Ltd.
Tel
021-58958002 18930822973
Email
sales@uhnshanghai.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Shanghai Rechem science Co., Ltd.
Tel
021-31433387 15618786686
Email
sales@rechemscience.com